EIKN Earnings Results and History
Eikon Therapeutics, Inc.'s earnings at a glance: the latest results and outlook from the press release, revenue, margins and EPS for every quarter from the company's SEC filings, and how the stock moved after each report. New results show here within about a minute of being filed.
- EPS−$1.59 vs −$1.74 est +8.6%
- Revenue–
Filed ยท Press release
Key takeaways
from the press release- Net loss widened to $86.1M ($1.59 per share) from $71.1M a year earlier as R&D spending rose 21%.
- Cash and marketable securities of $461.7M; runway extended into the first quarter of 2028.
Filings and dates
SEC EDGAR- Nov 12, 2026Earnings release, Q3 20268-K Press release
Also see EIKN institutional ownership and the earnings calendar.
EIKN earnings FAQ
What were EIKN's latest earnings?
For Q3 2026 Eikon Therapeutics, Inc. reported, GAAP EPS of -$1.59. The results were filed with the SEC on Nov 12, 2026.
When is EIKN's next earnings date?
There is no confirmed date on our calendar yet. Most companies report about four to six weeks after each quarter ends.
Where do these numbers come from?
Results, guidance and financials come from Eikon Therapeutics, Inc.'s own SEC filings: the earnings press release (Form 8-K) and the quarterly and annual reports (10-Q and 10-K). Key takeaways summarize the press release. Estimates and price moves come from market data.
For informational and educational purposes only. Not investment advice, and not a recommendation to buy or sell any security. Results come from company filings with the SEC. Estimates are consensus figures from before each report. Key takeaways summarize the company's press release and may contain errors; the press release is the authoritative source.